INVEGA HAFYERA Suppliers: Who Manufactures, Supplies, and Licenses Paliperidone Palmitate (6-Month) Globally
Last updated: May 27, 2026
Executive summary
INVEGA HAFYERA (paliperidone palmitate) is marketed in the US by Janssen Products, LP (Johnson & Johnson).
The core global supply chain is built around Janssen’s biologic-style long-acting injectable manufacturing model for sterile injectables: drug substance (as applicable) and final sterile drug product are produced by Janssen manufacturing sites and released through the Janssen commercial organization in the US and via regional distribution partners internationally.
Without a specific geography (US vs EU vs other markets) and without the Orange Book/NDA exhibits or local tender documentation, a complete supplier-by-supplier list (including specific plant addresses and third-party API/excipient suppliers) cannot be produced to a litigation-grade standard from publicly indexed records alone.
Who supplies INVEGA HAFYERA in the US (NDA holder, manufacturer, and distributors)?
Commercial product distribution: through the Janssen distribution network in the US for INVEGA HAFYERA.
What “supplier” usually means for LAIs
For long-acting injectable (LAI) antipsychotics like INVEGA HAFYERA, “supplier” in procurement and regulatory work typically maps to:
NDA/labeler entity (responsible for supply, pharmacovigilance, and US regulatory commitments).
Contract manufacturing site(s) for sterile drug product.
Upstream suppliers for drug substance/intermediates and critical excipients (often disclosed only in procurement contracts or regulatory module-level details, not always in public indexes).
What companies manufacture the paliperidone palmitate 6-month injection used in INVEGA HAFYERA?
Answer:
INVEGA HAFYERA is manufactured under the Janssen commercial and manufacturing network for sterile, long-acting depot formulations.
Public sources generally identify the labeler and broad manufacturing responsibility, but do not consistently disclose a full vendor stack (API producer, sterilization vendor, vial/syringe container supplier) at the same granularity across markets.
Is the API supplied by a third party or manufactured in-house?
Answer (publicly confirmable level):
INVEGA HAFYERA’s active is paliperidone palmitate (paliperidone palmitate is the long-acting ester).
Publicly available label-level documentation often does not name the specific API manufacturer when “Janssen” is listed as the product’s manufacturer/holder for regulatory purposes.
Which sterile injectable manufacturing steps create the supplier bottleneck?
Aseptic processing and terminal sterilization strategy (depending on the final dosage form and process validation approach).
Particle size control and depot suspension reproducibility for paliperidone palmitate.
Container closure system suitability (vials, stoppers, labeling, and secondary packaging) and cold-chain or ambient controls during distribution.
What formulations are supplied for INVEGA HAFYERA (dosage strengths, vial presentation, and administration kit)?
Answer:
INVEGA HAFYERA is a once-every-6-month intramuscular (IM) depot injection containing paliperidone palmitate suspension.
Procurement-relevant presentation points
Product is supplied as a sterile injectable depot suspension with manufacturer-specified injection technique requirements (IM route).
The “kit” is typically a product-specific presentation in the market, but the exact packaging configuration and whether a separate administration system is included varies by market.
Does INVEGA HAFYERA have biosimilar or generic suppliers entering the supply chain?
Answer:
INVEGA HAFYERA is a branded LAI. Competing supply through biosimilar or generic paliperidone palmitate depots depends on regulatory pathway and patent status by market.
Without tying this to a specific jurisdiction and date, a definitive “supplier transition” view is not supportable from public indexing alone.
What is the Orange Book status of INVEGA HAFYERA and how does it affect supplier risk?
Answer:
INVEGA HAFYERA is regulated as a small-molecule drug product (not a biologic), so it can be listed in the US Orange Book for reference listed drug and patents.
Supplier risk and generic entry timing depends on expiration of listed patents and exclusivities.
Why this matters for procurement
If patents block generic LAI entry, manufacturers and distributors remain dominated by brand supply.
If a Paragraph IV generic is filed and approved, supplier diversification can occur through distribution of the first entrants.
How do international markets change INVEGA HAFYERA supplier identification?
Answer:
In non-US markets, procurement documents often show:
local marketing authorization holder,
local distributor/importer,
manufacturing site(s) for the product released in-country.
Janssen may use different importers/distributors and may route product through different logistics partners.
Key supplier map (what can be stated at high confidence from label-level public records)
Supply-chain layer
Entity type
Publicly supported identification level
Label holder / NDA sponsor (US)
US commercialization and regulatory accountability
Janssen Products, LP
Product manufacturer (sterile depot)
Site-level manufacturing responsibility
Janssen manufacturing network (site names not reliably extractable at vendor level from public indexes)
Regional distributors
Country import/distribution
varies by market; typically Janssen regional entities or appointed importers/distributors
Upstream API/excipient suppliers
API and critical input vendors
generally not fully disclosed at vendor stack level in public label text
What supplier diligence should buyers run for INVEGA HAFYERA (contracting and continuity)?
Even with limited vendor disclosure in public indexes, diligence can focus on what procurement teams control:
Confirm GMP site responsible for the specific commercial lot.
Confirm supply continuity plans for sterile manufacturing (single-site vs multi-site redundancy).
Verify container closure and visual inspection standards tied to depot suspension stability.
Audit distribution qualifications (temperature monitoring, excursion handling, and return rules).
Key Takeaways
The US commercial responsibility for INVEGA HAFYERA is with Janssen Products, LP.
Manufacturing responsibility sits within Janssen’s sterile injectable LAI supply network, but a vendor-by-vendor supplier roster (API producer, vial/stopper supplier, sterile filtration/sterilization subcontractors) is not consistently public at the granularity needed for a precise “suppliers list.”
International “supplier” identification changes by market through local importers and distributors, even when the labeler is Janssen.
FAQs
Who is the marketing authorization holder for INVEGA HAFYERA outside the US?
Which manufacturing plants produce paliperidone palmitate LAI suspension for INVEGA HAFYERA?
Are there contract manufacturers or only Janssen-owned facilities for INVEGA HAFYERA?
How can procurement teams verify the manufacturing site for each INVEGA HAFYERA lot?
What distribution partners typically supply INVEGA HAFYERA at country level (importer vs distributor roles)?
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
